1. Home
  2. KYMR vs CURB Comparison

KYMR vs CURB Comparison

Compare KYMR & CURB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KYMR
  • CURB
  • Stock Information
  • Founded
  • KYMR 2015
  • CURB 2024
  • Country
  • KYMR United States
  • CURB United States
  • Employees
  • KYMR N/A
  • CURB N/A
  • Industry
  • KYMR Medicinal Chemicals and Botanical Products
  • CURB
  • Sector
  • KYMR Health Care
  • CURB
  • Exchange
  • KYMR Nasdaq
  • CURB NYSE
  • Market Cap
  • KYMR 3.0B
  • CURB 2.5B
  • IPO Year
  • KYMR 2020
  • CURB N/A
  • Fundamental
  • Price
  • KYMR $42.30
  • CURB $23.18
  • Analyst Decision
  • KYMR Buy
  • CURB Buy
  • Analyst Count
  • KYMR 16
  • CURB 5
  • Target Price
  • KYMR $54.00
  • CURB $25.69
  • AVG Volume (30 Days)
  • KYMR 456.9K
  • CURB 461.8K
  • Earning Date
  • KYMR 10-31-2024
  • CURB 02-07-2025
  • Dividend Yield
  • KYMR N/A
  • CURB N/A
  • EPS Growth
  • KYMR N/A
  • CURB N/A
  • EPS
  • KYMR N/A
  • CURB 0.06
  • Revenue
  • KYMR $87,563,000.00
  • CURB $111,428,000.00
  • Revenue This Year
  • KYMR N/A
  • CURB N/A
  • Revenue Next Year
  • KYMR $33.16
  • CURB N/A
  • P/E Ratio
  • KYMR N/A
  • CURB $381.51
  • Revenue Growth
  • KYMR 86.92
  • CURB 52.36
  • 52 Week Low
  • KYMR $22.35
  • CURB $18.80
  • 52 Week High
  • KYMR $53.27
  • CURB $25.35
  • Technical
  • Relative Strength Index (RSI)
  • KYMR 41.34
  • CURB N/A
  • Support Level
  • KYMR $40.95
  • CURB N/A
  • Resistance Level
  • KYMR $44.17
  • CURB N/A
  • Average True Range (ATR)
  • KYMR 2.32
  • CURB 0.00
  • MACD
  • KYMR -0.33
  • CURB 0.00
  • Stochastic Oscillator
  • KYMR 16.07
  • CURB 0.00

About KYMR Kymera Therapeutics Inc.

Kymera Therapeutics Inc is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body's innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Kymera's Pegasus targeted protein degradation platform harnesses the body's natural protein recycling machinery to degrade disease-causing proteins, with a focus on un-drugged nodes in validated pathways currently inaccessible with conventional therapeutics. It is accelerating drug discovery with an unmatched ability to target and degrade intractable proteins and advance new treatment options for patients.

About CURB CURBLINE PPTYS CORP

Curbline Properties Corp is a publicly-traded REIT operating Convenience retail properties, offering enhanced access and visibility relative to other retail property types. The properties generally consist of a ubiquitous row of shop units along with dedicated parking leased to a diversified mixture of national and local service and restaurant tenants that cater to daily convenience trips from the growing suburban population.

Share on Social Networks: